U2AF2 and central nervous system cancer: And in TCGA samples, 5.9% of grade 3 gliomas with IDH1 mutation/1p19q co-deletion harbored mutations in U2AF2 while no mutations were found in grade 2 gliomas with the same molecular signature (Figure 6).